Neurodegenerative diseases
Drug research and approvals for neurodegenerative diseases: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 1,861 studies of neurodegenerative diseases are recruiting on ClinicalTrials.gov, and Health Canada has authorized 6 drug trials for it since 2013.
- Recruiting worldwide: 1,861
- Trials authorized in Canada: 6
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 1,861 recruiting on ClinicalTrials.gov ↗- Tau Pathology in the Brain After Hip or Knee Replacement SurgeryNCT07871487 · Not reported · Uppsala University Hospital · starts Apr 1, 2029
- Strength and Dual-Task on Sarcopenia in People With Parkinson's DiseaseNCT07907302 · Not applicable · University of Valencia · starts Jan 11, 2027
- Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)NCT07521930 · Not applicable · Johns Hopkins University · starts Jan 1, 2027
- Decoding the Neural Mechanisms Underlying Postural Instability and Gait Dysfunction in Parkinson's DiseaseNCT07748962 · Not applicable · The Cleveland Clinic · starts Dec 9, 2026
- VOCALE LBD: Online Peer Support for Caregivers of People With Lewy Body DementiaNCT07637097 · Not applicable · University of Washington · starts Dec 1, 2026
- Bayesian Optimization of DBS for GaitNCT07835308 · Early Phase 1 · University of Minnesota · starts Dec 1, 2026
- Investigating Basal Ganglia-Cortical Physiology During Sleep and Its Modulation by Adaptive Deep Brain Stimulation in…NCT07808346 · Not applicable · University of Colorado, Denver · starts Dec 1, 2026
- Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon CancerNCT07808151 · Phase 2 · Solstice Oncology, Inc. · starts Nov 30, 2026
- Exploratory Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's DiseaseNCT07911670 · Early Phase 1 · The First Affiliated Hospital of Anhui Medical University · starts Nov 23, 2026
- Retraining Gait in Parkinson's Disease Via a Personalised AppNCT07584993 · Not applicable · Northumbria University · starts Nov 19, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Apr 13, 2026 | A phase 3 open-label extension study to investigate the long-term safety and efficacy of orally administered nnz-2591 in pediatric participants with…ERCANETIDE (NNZ-2591) | NEUREN PHARMACEUTICALS LTD. | Pending |
| Feb 6, 2026 | A randomized, placebo-controlled, double-blind, phase 2 trial of fampridine in patients with autosomal recessive spastic ataxia of charlevoix-saguenay (arsacs)FAMPRIDINE | MCGILL UNIVERSITY | Pending |
| Dec 9, 2024 | A phase 2/3 double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of fosigotifator in subjects 6 years or older…FOSIGOTIFATOR (ABBV-CLS-7262) | AbbVie | Pending |
| Sep 26, 2023 | A continuation study of latozinemab in participants with neurodegenerative diseaseAL001 (RECOMBINANT HUMAN ANTIHUMAN SORT1 MONOCLONAL ANTIBODY) | ALECTOR INC | Closed |
| Jan 3, 2014 | The brain-eye amyloid memory (beam) study: valadation of ocular measures as potential biomarkers for early detection amyloid and neurodegenerationFLUTEMETAMOL F18 INJECTION | SUNNYBROOK RESEARCH INSTITUTE | Ongoing |
| Sep 18, 2013 | Advanced molecular neuroimaging techniques for diagnosis and prognosis in neurodegenerative diseasesGLUDEF ([18F]FDG(2-DEOXY-2-[18F]FLUORO-D-GLUCOSE) | ST JOSEPHS HEALTH CENTRE LONDON | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA